AbbVie
ABBV
1,692 hedge funds and large institutions have $68.3B invested in AbbVie in 2016 Q4 according to their latest regulatory filings, with 146 funds opening new positions, 649 increasing their positions, 668 reducing their positions, and 85 closing their positions.
72% more first-time investments, than exits
New positions opened: 146 | Existing positions closed: 85
5% more funds holding in top 10
Funds holding in top 10: 81 → 85 (+4)
2% more funds holding
Funds holding: 1,654 → 1,692 (+38)
1% more call options, than puts
Call options by funds: $1.06B | Put options by funds: $1.04B
3% less capital invested
Capital invested by funds: $70.1B → $68.3B (-$1.78B)
3% less repeat investments, than reductions
Existing positions increased: 649 | Existing positions reduced: 668
1.1% less ownership
Funds ownership: 68.28% → 67.19% (-1.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$836M |
| 2 |
AIG
American International Group
New York
|
+$426M |
| 3 |
GCM
Glenview Capital Management
New York
|
+$188M |
| 4 |
State Street
Boston,
Massachusetts
|
+$169M |
| 5 |
Asset Management One
Tokyo,
Japan
|
+$141M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$773M |
| 2 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$383M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$313M |
| 4 |
JP Morgan Chase
New York
|
-$237M |
| 5 |
MTB
Mizuho Trust & Banking
Tokyo,
Japan
|
-$163M |
ABBV Hedge Fund Activity: Q4 2016 in Review
1,692 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q4 2016, worth a combined $68.3B — down 2.5% from $70.1B a quarter earlier.
Buyers outnumbered sellers: 146 funds opened new ABBV positions and 85 closed out — a net gain of 61 holders — while 649 added to existing stakes and 668 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $836M. The largest seller was Baker Bros. Advisors, cutting an estimated $773M.
- 1,692 institutional investors held AbbVie (ABBV) as of Q4 2016, up from 1,654 in Q3 2016.
- Funds reported $68.3B of AbbVie stock for Q4 2016, down 2.5% quarter-over-quarter.
- 146 funds opened new AbbVie positions in Q4 2016 and 85 closed out, a net change of +61 holders.
- The largest AbbVie buyer in Q4 2016 was Capital Research Global Investors, an estimated $836M added.
- The largest AbbVie seller in Q4 2016 was Baker Bros. Advisors, an estimated $773M sold.
Based on aggregated 13F filings for Q4 2016.